What are indigenous medical devices in India?

Medical devices manufactured domestically rather than imported—including orthopedic implants, cardiac stents, diagnostic equipment, and surgical instruments. As of 2026, 60–70% of India's ₹45,000 crore medical devices market is still imported, driven by lack of domestic manufacturing capacity and capability. Government policy under Union Minister Jitendra Singh's leadership actively incentivizes domestic production to reduce costs and improve healthcare accessibility.

How much does it cost to start medical device manufacturing in India?

₹5–15 crore minimum for MVP (manufacturing facility, equipment, ISO 13485 certification, CDSCO approval, regulatory consulting, initial inventory, working capital). Breakdown: facility & equipment ₹2–4 crore, regulatory & compliance ₹50–100 lakh, R&D & tooling ₹1–2 crore, working capital ₹1–3 crore. Government PLI scheme offers ₹50–100 lakh in support for early-stage manufacturers.

Is medical device manufacturing profitable in India?

Yes. Gross margins of 40–50% are typical for mid-range devices. A manufacturer producing 50–100 orthopedic implants per month at ₹5–10 lakh per unit generates ₹2.5–5 crore annual revenue with 35–45% net margins after compliance & distribution costs. Government procurement (e-tendering via NITI Aayog, state health departments) adds 15–20% volume at negotiated pricing. Payback period: 3–5 years.

What regulations apply to medical device manufacturing in India?

CDSCO approval is mandatory under Medical Devices Rules 2017. ISO 13485:2016 (quality management) certification is required. Customs duty exemption available under Production-Linked Incentive (PLI) Scheme for medical devices (5–10% concessional duty vs. 10–20% standard). GST 5% applicable. Technology transfer agreements require FEMA compliance. State healthcare procurement follow GeM (Government e-Marketplace) norms and state-specific tender regulations.

Medical Devices Manufacturing India 2026 — Business Guide

AI SummaryIndia's medical devices market, valued at ₹45,000–₹55,000 crore in 2026, remains 60–70% import-dependent, creating a critical opportunity for domestic manufacturers. Union Minister Jitendra Singh has publicly stated that India is transitioning from an import-dependent healthcare system to one driven by indigenous capabilities, with government backing via the Production-Linked Incentive (PLI) scheme offering ₹3,000 crore in support. Entrepreneurs and established manufacturers with access to ₹5–15 crore capital, technology partnerships, and regulatory expertise should pursue contract manufacturing of orthopedic implants, cardiac stents, and diagnostic devices for hospital and government procurement channels—offering 35–45% net margins and 3–5 year payback periods.